The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

The ASX rises on positive US inflation news, Xero ticks up 5% and Bitcoin hits US$93k before cooling off a tad.

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

Leading the charge was Xero (ASX:XRO), which soared 6 per cent after the accounting software company revealed a stellar ...

It's been spectacularly successful, but with $17 billion-a-year Keytruda (pembrolizumab) now accounting for more than a third of its total sales there has been pressure on the company to diversify.